This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kobayashi, H. Articles by Brechbiel, M. W. Search for Related Content PubMed PubMed Citation Articles by Kobayashi, H. Articles by Brechbiel, M. W.

Application of a Macromolecular Contrast Agent for Detection of Alterations of Tumor Vessel Permeability Induced by Radiation

¹ Metabolism Branch, ² Radiation Biology Branch, and ³ Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland

Permeability of tumor vasculature can be a major barrier to successful drug delivery, particularly for high molecular weight agents such as monoclonal antibodies and their diagnostic or therapeutic conjugates. In this study, changes in permeability of SCCVII tumor vessels after radiation treatment were evaluated by dynamic magnetic resonance imaging as a function of time after irradiation using a generation-8 polyamidoamine dendrimer (G8-Gd-D)-based magnetic resonance imaging contrast agent shown previously to be confined to tumor blood vessels. Tumor irradiation consisted of either single doses (2–15 Gy) or various daily fractionated doses (5 days). A single radiation dose of 15 Gy resulted in significant transient image enhancement of the tumor tissue with a maximum occurring between 7 and 24 hours after radiation treatment. No observable enhancement was recorded for fractionated radiation doses. Use of dynamic magnetic resonance imaging coupled with G8-Gd-D provides an exquisite methodology capable of defining the timing of enhanced permeability of macromolecules in tumors after irradiation. Such information might be applied to optimize the efficacy of subsequent or concurrent therapies including radiolabeled antibodies or other anticancer agents in combination with external beam therapies.

This article has been cited by other articles:

				D. L. Schwartz, G. Powis, A. Thitai-Kumar, Y. He, J. Bankson, R. Williams, R. Lemos, J. Oh, A. Volgin, S. Soghomonyan, et al. The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects Mol. Cancer Ther., April 1, 2009; 8(4): 947 - 958. [Abstract] [Full Text] [PDF]

				P. L. Choyke Magnetic Resonance Techniques for Early and Late Cancer Therapy Trials Am. Assoc. Cancer Res. Educ. Book, April 1, 2006; 2006(1): 140 - 142. [Full Text] [PDF]